Clinical Trial

Assessment of Acute Psychomotor Agitation Measures Associated With Schizophrenia and Bipolar Disorder

Completed Phase 2
View on ClinicalTrials.gov →
Summary
This open-label study will utilize treatment with BXCL501 in order to assess the suitability of patient-and lay informant-assessed outcome measures for evaluation of severity of psychomotor agitation episodes in patients with Bipolar Disorders, Schizophrenia, Schizoaffective, and Schizophreniform disorders and correlate them with clinician-assessed ratings.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-08-08; most recent amendment 2026-04-01.
Status change: Active, Not Recruiting → Completed 2026-04-01
Status change: Recruiting → Active, Not Recruiting 2025-09-12
Trial Details
NCT Number NCT07116694
Lead Sponsor BioXcel Therapeutics Inc
Collaborators: Premier Research
Conditions Bipolar I Disorder, Bipolar II Disorder, Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders, Psychomotor Agitation
Enrollment 33 participants
Start Date 2025-06-19
Primary Completion 2025-10-07 (estimated)
Study Completion 2025-10-07 (estimated)
Updated on ClinicalTrials.gov 2026-08-06